Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2012

Kim J, Kim W-, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle. 2012;11(6):1123-30.

Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget. 2012;3(6):651-63.

Kim J, Keay SK, You S, Loda M, Freeman MR. A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2. PLoS One. 2012;7(12):e50392.

Magro CM, Yang S-, Zippin JH, Zembowicz A. Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins. Arch Pathol Lab Med. 2012;136(12):1558-64.

Deem AK, Li X, Tyler JK. Epigenetic regulation of genomic integrity. Chromosoma. 2012;121(2):131-51.

Du J, Leng J, Habegger L, Sboner A, McDermott D, Gerstein M. IQSeq: integrated isoform quantification analysis based on next-generation sequencing. PLoS One. 2012;7(1):e29175.

Esgueva R, Park K, Kim R, Kitabayashi N, Barbieri CE, Dorsey PJ, et al. Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium. Diagn Mol Pathol. 2012;21(2):61-8.

Acheampong MG, Dueño DE, Glover BK, Henry AA, Mata R, Vanbrakle ML, et al. Acetylcholinesterase: substrate traffic and inhibition. Biochem Mol Biol Educ. 2012;40(2):144.

Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20):4597-607.

Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321-5.